Actually, the big problem in the US is that there are no alternatives. The last Mylan competitor making a similar product folded six months ago. If you want to blame anything about the US system for the current situation, blame the regulatory capture that is generic drug approval.
What does the NHS do about drugs that are sole source?
What does the NHS do about drugs that are sole source?